ZEPENDO owner Contact Information online
from Actelion Pharmaceuticals Ltd.
ZEPENDO
US serial number:85000416
Application filling date:Mar. 29, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:Nov. 16, 2010
Publication date:Aug. 31, 2010
Standard character claim:Yes. The mark consists of standard characters without claim to any particular font style, size, or color.
Mark drawing type:4 - STANDARD CHARACTER MARK
Foreign priority claimed:Yes
Foreign foreign application number:61332/2009
Foreign foreign application filling date:Oct. 13, 2009
Foreign foreign registration number:592571
Foreign foreign registration date:Oct. 23, 2009
Foreign foreign application registration country:SWITZERLAND
Foreign foreign expiration date:Oct. 13, 2019
Goods and services:For: Pharmaceutical Preparations for the treatment of cerebrovascular, cardiovascular, pulmonary and inflammatory indications as well as for the treatment of cancer
International Class(es): 005- Primary Class
U.S Class(es): 006,018,044,046,051,052
Class S
Services:Pharmaceutical Preparations for the treatment of cerebrovascular
cardiovascular
pulmonary and inflammatory indications as well as for the treatment of cancer
Current owner owner name:Actelion Pharmaceuticals Ltd.
Current owner owner address:Gewerbestrasse 16
Allschwil
SWITZERLAND
CH-4123
Current owner legal entity type:CORPORATION
Current owner state or country:SWITZERLAND
Attorney name:Scott D. Woldow
Attorney email:sdwoldow@sgrlaw.com
Attorney docket number:034406.015
Attorney email authorized:No
Correspondent name address:Scott D. Woldow
SMITH, GAMBRELL & RUSSELL, LLP
1055 Thomas Jefferson St., NW
Suite 400
WASHINGTON,
DISTRICT OF COLUMBIA
UNITED STATES
20007
Correspondent phone:202-973-2612
Correspondent email:sdwoldow@sgrlaw.com
docketing@sgrlaw.com
Correspondent fax:202-973-2612
Correspondent email authorized ZEPENDO:Yes
Latest trademarks
Popular owners
Glaxo Group Limited (173) Novartis AG (130) JOHNSON & JOHNSON (124) Millennium Pharmaceuticals, Inc. (54) Eli Lilly and Company (51) Windmill Health Products, LLC (46) Bayer Aktiengesellschaft (44) SANOFI (41) Wyeth LLC (41) Pfizer Inc. (39) Forest Laboratories, Inc. (34) Bristol-Myers Squibb Company (33) Vital Health Pharmaceuticals, Inc. (31) Primary Investments Group Limited (28) S. C. Johnson & Son, Inc. (28) MERCK SHARP & DOHME CORP. (27) Futurebiotics, LLC (26) MONSTER ENERGY COMPANY (19) Scott Riddell (17) Biocept, Inc. (16)Popular publication dates
Aug. 31, 2010 Mar. 08, 2011 Mar. 15, 2011 Mar. 22, 2011 Nov. 16, 2010 Mar. 29, 2011 Apr. 19, 2011 Apr. 12, 2011 Oct. 19, 2010 Oct. 26, 2010 Apr. 26, 2011 Feb. 15, 2011 Oct. 05, 2010 Oct. 12, 2010 Jan. 25, 2011 Sep. 21, 2010 Jan. 11, 2011 Feb. 22, 2011 Nov. 23, 2010 Sep. 28, 2010Similar brands
